Intest Res.  2020 Jan;18(1):45-55. 10.5217/ir.2019.00039.

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study

• Saruta M
• Park DI
• Kim YH
• Yang SK
• Jang BI
• Cheon JH
• Im JP
• Kanai T
• Katsuno T
• Ishiguro Y
• Nagaoka M
• Isogawa N
• Li Y
• Banerjee A
• Ahmad A
• Hassan-Zahraee M
• Clare R
• Gorelick K
• Cataldi F
• Watanabe M
• Hibi T

• KMID: 2501366
• DOI: http://doi.org/10.5217/ir.2019.00039

Abstract

Background/Aims
PF-00547659 is a monoclonal antibody against human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) that prevents the binding of α4β7+ lymphocytes to MAdCAM-expressing sites in the gastrointestinal tract with high affinity and selectivity, and is being developed for the treatment of Crohn’s disease (CD).
Methods
OPERA is a randomized, multicenter, double-blind, placebo-controlled study to investigate the efficacy, safety, and pharmacokinetics of PF-00547659 following subcutaneous administration in subjects with active CD, a history of failure or intolerance to anti-tumor necrosis factor and/or immunosuppressants, high-sensitivity C-reactive protein > 3.0 mg/L, and ulcers on colonoscopy. The primary endpoint was Crohn’s Disease Activity Index-70 response at week 8 or 12. Subpopulation analyses for Asian subjects were performed as some differences are observed in genetics and clinical phenotypes in Asian CD patients compared with Western patients.
Results
In this study, 265 CD subjects were randomized, with a subpopulation of 21 subjects (8 Japanese and 13 Korean) defined as the Asian population. In the overall and Asian populations; PF-00547659 was pharmacologically active as evidenced by soluble MAdCAM and circulating β7+ central memory CD4+ T-lymphocytes, although no clear evidence of efficacy was observed in any clinical endpoints; pharmacokinetics of PF-00547659 in the Asian subpopulation was generally comparable to the overall population; and the safety profile of PF-00547659 appeared acceptable up to 12 weeks of treatment.
Conclusions
In the overall and Asian populations, efficacy of PF-00547659 could not be demonstrated using any clinical endpoints compared with placebo. Pharmacokinetics and safety of PF-00547659 were generally comparable. Further studies with larger numbers of patients are required to confirm our results. (Trial Registration Number: NCT01276509)

Keyword

PF-00547659; MAdCAM; Crohn disease; Japanese; Korean

Figure

• 

  Fig. 1. Comparison of (A, B) primary endpoint (CDAI-70 response rates at weeks 8 and 12) and (C, D) secondary endpoint (CDAI-100 response rates at weeks 8 and 12) between the (A, C) overall and (B, D) Asian (Japanese and Korean) populations. mITT, modified intent-to-treat population.

• 

  Fig. 2. Comparison of secondary endpoint (CDAI remission rates at weeks 2, 4, 6, 8, 10, and 12) between the (A) overall and (B) Asian (Japanese and Korean) populations. mITT, modified intent-to-treat population.

• 

  Fig. 3. Results of the post hoc analysis (CDAI remission rates at weeks 8 and 12) between the (A) overall and (B) Asian (Japanese and Korean) populations with baseline CRP >18.8 mg/L. The generalized linear mixed model (GLMM) contains fixed factors of treatment, the status of anti-TNF experience, the concomitant immunosuppressive therapy, baseline value, visit and treatment by visit, and a random effect of subject. mITT, modified intent-to-treat population.

• 

  Fig. 4. Changes of hs-CRP at weeks 0, 4, 8, and 12 (A, B), percentage of β7+ central memory CD4+ T-lymphocytes*MESF at weeks 0, 8, and 12 (C, D), and changes of soluble MAdCAM at weeks 0, 2, 10, and 12 (E, F) in the (A, C, E) overall and (B, D, F) Asian (Japanese and Korean) populations. Error bars in the overall population denote 90% CIs. hs-CRP, high-sensitivity CRP; MESF, Molecules of Equivalent Soluble Fluorochrome; MAdCAM, mucosal addressin cell adhesion molecule; mITT, modified intent-to-treat population.

Reference

1. Fiocchi C. Inflammatory bowel disease pathogenesis: where are we? J Gastroenterol Hepatol. 2015; 30 Suppl 1:12–18.

2. Streeter PR, Berg EL, Rouse BT, Bargatze RF, Butcher EC. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature. 1988; 331:41–46.

3. Nakache M, Berg EL, Streeter PR, Butcher EC. The mucosal vascular addressin is a tissue-specific endothelial cell adhesion molecule for circulating lymphocytes. Nature. 1989; 337:179–181.

4. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997; 151:97–110.

5. Pullen N, Molloy E, Carter D, et al. Pharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibody. Br J Pharmacol. 2009; 157:281–293.

6. Sandborn WJ, Lee SD, Tarabar D, et al. Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study. Gut. 2018; 67:1824–1835.

7. Ng SC. Epidemiology of inflammatory bowel disease: focus on Asia. Best Pract Res Clin Gastroenterol. 2014; 28:363–372.

8. Sands BE, Katz S, Wolf DC, et al. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn’s disease. Gut. 2013; 62:1288–1294.

9. Park SC, Jeen YT. Genetic studies of inflammatory bowel disease-focusing on Asian patients. Cells. 2019; 8:E404.

10. Introductory guide MedDRA version 18.1, 2015. MedDRA Web site. https://www.meddra.org/sites/default/files/guidance/file/intguide_18_1_english.pdf. Accessed Jan 16, 2020.

11. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013; 369:711–721.

12. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005; 129:807–818.

13. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology. 2007; 132:1672–1683.

14. Sandborn WJ, Schreiber S, Feagan BG, et al. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011; 9:670–678.

15. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010; 362:1383–1395.

16. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol. 2006; 72:1–10.

17. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009; 49:1012–1024.